Tag Archives: Sanofi’s Efdoralprin Alfa Shows Superior Results in Phase 2 AATD Emphysema Trial

Efdoralprin Alfa Meets All Endpoints in Sanofi’s Phase 2 Study, Paving Way for First Recombinant Therapy in AATD

(IN BRIEF) Sanofi’s investigational therapy efdoralprin alfa met all primary and key secondary endpoints in the Phase 2 ElevAATe study for alpha-1 antitrypsin deficiency emphysema, demonstrating superior efficacy compared to standard plasma-derived therapy. The results highlight its potential as the … Read the full press release